A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer

Journal of Pain and Symptom Management

Volumn 19, Issue 6, 2000, Pages 427-435

  Bruera, Eduardo ^a   Belzile, Michelle ^b   Neumann, Catherine ^b   Harsanyi, Zoltan ^c   Babul, Najib ^c   Darke, Andrew ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b GREY NUNS COMMUNITY HOSPITAL   (Canada)

^c Purdue Frederick ^*  (Canada)

Author keywords

Anorexia; Bloating; Cancer associated dyspepsia syndrome; Controlled release; Metoclopramide; Vomiting

Indexed keywords

ANTIEMETIC AGENT; METOCLOPRAMIDE; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; HUMAN; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; VOMITING;

AGED; ANTIEMETICS; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METOCLOPRAMIDE; MIDDLE AGED; NAUSEA; NEOPLASMS; PLACEBOS;

EID: 0033936966     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(00)00138-X     Document Type: Article

References (42)

1. Reuben D.B., Mor V. Nausea and vomiting in terminal cancer patients. Arch Intern Med. 146:1986;2021-2023.
2. Baines M. Nausea and vomiting in the patient with advanced cancer. J Pain Symptom Manage. 3:1988;81-85.
3. Bruera E. Update on adjuvant drugs in patients with cancer. Bond M.R., Charlton J.E., Woolf C.J. Proceedings World Congress on Pain. 1991;459-465 Elsevier Science Publications BV, New York.
4. Curtis E.B., Krech R., Walsh T.D. Common symptoms in patients with advanced cancer. J Palliat Care. 7:1991;25-29.
5. Bruera E., Seifert L., Watanabe S., Babul N., Darke A., Harsanyi Z., Suarez-Almazor M. Chronic nausea in advanced cancer patients. a retrospective assessment of a metoclopramide-based antiemetic regimen J Pain Symptom Manage. 11:1996;147-153.
6. Pereira J., Bruera E. Chronic nausea. Bruera E., Higginson I. Cachexia-anorexia in cancer patients. 1996;23-37 Oxford University Press, Oxford.
7. Nelson K.A., Walsh D.T., Sheehan F.G., O'Donovan P.B., Falk G.W. Assessment of upper gastrointestinal motility in the cancer associated dyspepsia syndrome. J Palliat Care. 9:1993;27-31.
8. Rubin A., Winston J. The role of the vestibular apparatus in the production of nausea and vomiting following the administration of morphine to man. J Clin Invest. 29:1958;1261.
9. Comroe J.H., Dripps R.D. Reactions to morphine in ambulatory and bed patients. Surg Gynecol Obstet. 87:1948;221.
10. Bellville J.W., Bross I.D.J., Howland W.S. Postoperative nausea and vomiting. IV. Factors related to postoperative nausea and vomiting. Anesthesiology. 21:1960;186.
11. Burtles R., Peckett B.W. Postoperative vomiting. Br J Anaesth. 29:1957;114.
12. Riding J.E. Minor complications of general anesthesia. Br J Anaesth. 47:1975;91.
13. Borrison H.L., Wang S.C. Physiology and pharmacology of vomiting. Pharmacol Rev. 5:1953;193-230.
14. Costello D.J., Borrison H.L. Naloxone antagonises narcotic self-blockade of emesis in the cat. J Pharmacol Exp Ther. 203:1977;222-230.
15. Manara L., Bianchetti A. The central and peripheral influence of opioids on gastrointestinal propulsion. Ann Rev Pharmacol Toxicol. 25:1985;249-273.
16. Lichter I. Which antiemetic? J Palliat Care. 1:1993;42-50.
17. Milner W.D., Sanger G.H. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 88:1986;497-499.
18. Fozard JR. Basic mechanism of antimigraine drugs. In: Advances in Neurology. Headache: Physiopathological and clinical concepts (Critchley M, Friedman AP, Goroni AS, Sicuter F, eds.). New York: Raven Press, 1982;33:295-307.
19. Fozard J.R., Mabarok Ali A.T.M. Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmac. 49:1978;109-112.
20. Ripamonti C, Rodriguez C. Gastrointestinal motility disorders in patients with advanced cancer. In: Topics in palliative care. New York: Oxford University Press, 1997;61-93.
21. Harrington R.A., Hamilton C.W., Brogden R.N., Linkewich J.A., Romankiewicz J.A., Heel R.C. Metoclopramide. an updated review of its pharmacologic properties and clinical use Drugs. 25:1983;451-494.
22. Gralla R.J., Itri L.M., Pisko S.E., Squillante A.F., Kelsen D.P., Braun D.W. Jr., Bordin L.A., Braun T.I., Young C.W. Antiemetic efficacy of high-dose metoclopramide. randomized trials with placebo and prochlorpepazinel in patients with chemotherapy-induced nausea and vomiting N Engl J Med. 16:1981;905-909.
23. Schwartz J.-C., Agid Y., Bouthenet M.-L.et al. Neurochemical investigations into the human area postrema. Davis C.J., Lake-Bakaar G.V., Grahame-Smith D.G. Nausea and vomiting. mechanisms and treatment:1986;10-17 Springer-Verlag, Berlin.
24. Perkel M.S., Moore C., Hersh T., Davidson E.D. Metoclopramide therapy in patients with delayed gastric emptying. a randomized, double-blind study Dig Dis Sci. 24:1979;662-666.
25. Snape W.J., Battle W.M., Schwartz S.S., Braunstein S.N., Goldstein H.A., Avali A. Metoclopramide to treat gastroparesis due to diabetes mellitus. Ann Intern Med. 96:1982;444-446.
26. McCallum R.W., Ricci D.A., Rakatansky H., Behar J., Rhodes J.B., Salen G., Deren J., Ippoliti A., Olsen H.W., Palchuk K.et al. A multicentre placebo controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 6:1983;463-467.
27. Loo F.D., Palmer D.W., Soergel K.H., Kalbfleisch J.H., Wood C.M. Gastric emptying in patients with diabetes mellitus. Gastroenterology. 86:1984;485-494.
28. Shade R.R., Dugas M.C., Lhotsky D.M., Gavaler J.S., AanThiel D.H. Effect of metoclopramide on gastic liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci. 30:1985;10-15.
29. Dundee J.W., Clarke R.S.J. The premedicant and antiemetic action of metoclopramide. Postgrad Med J. 4(suppl 4):1973;34-37.
30. Assaf R.A.E., Clarke R.S.J., Dundee J.W., Samuel I.O. Studies of drugs given before anesthesia XXIV. metoclopramide and morphine and pethidine Br J Anaesth. 46:1974;514-519.
31. Bruera E., MacEachern T., Spachynski K., LeGatt D., MacDonald R.N., Babul N., Harsanyi Z., Darke A. Comparison of the efficacy, safety and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer. 74:1997;3204-3211.
32. Jaeschke R., Guyatt G.H. N of 1 randomized controlled clinical trials for investigations of quality of life in cancer. Osoba D. Effect of cancer on quality of life. 1991;65-67 CRC Press, Boca Raton.
33. Herrstedt J., Aapro M.S., Smyth J.F., Del Favero A. Corticosteroids, dopamine antagoinists and other drugs. Supp Care Canc. 6:1998;20-24.
34. Bruera E., Roca E., Cedaro L., Chacon R., Extevez R. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metaclopramide in patients resistant to metoclopramide. Cancer Treat Rep. 67:1983;381-383.
35. Kris M.G., Gralla R.J., Tyson L.B.et al. Improved control of cisplatin-induced emesis with high-dose metaclopramide and with combinations of metoclopramide, dexamethasone, and diphenyldramine. results of consecutive trials in 255 patients Cancer. 55:1985;527-534.
36. Sykes A.J., Kiltie A.E., Stewart A.L. Ondansetron versus chlorpomazine and dexamethasone combination for the prevention of nausea and vomiting. a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy Supp Care Canc. 5:1997;500-503.
37. Bruera E., Belzile M., Pituskin E.et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. 16:1998;3222-3229.
38. Bruera E., Sloan P., Mount B., Scott J., Suarez-Almozor M. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Clinical Trials Group. J Clin Oncol. 14:1996;1713-1717.
39. Bruera E., Fainsinger R., Spachynski K.et al. Clinical efficacy of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain. a randomized evaluation J Clin Oncol. 13:1995;1520-1527.
40. Bruera E., Ernst S., Hagen N.et al. Effectiveness of megestrol acetate in patients with advanced cancer. a randomized, double-blind, crossover study Canc Prev Contr. 2:1998;74-78.
41. Mannix K. Palliation of nausea and vomiting. Doyle D., Hanks G.W.C., MacDonald N. Oxford textbook of palliative medicine. 1998;489-499 Oxford University Press, Oxford.
42. Billings J.A. Outpatient management of advanced cancer. 1985;46-58 Lippincott, Philadelphia.